On November 6, 2017 Juno Therapeutics, Inc. (NASDAQ: JUNO) reported that it will webcast its presentations at two investor conferences in November (Press release, Juno, NOV 6, 2017, View Source;p=RssLanding&cat=news&id=2314671 [SID1234521607]). The presentations will feature a business overview and update by Steve Harr, Juno’s Chief Financial Officer and Head of Corporate Development.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Juno will present at the 26th Annual Credit Suisse Healthcare Conference at 9:15 a.m. Mountain Time (MT) on Wednesday, November 8, 2017.

Juno will present at the Evercore ISI Biopharma Catalyst / Deep Dive Conference at 8:45 a.m. Eastern Time (ET) on Wednesday, November 29, 2017.

The webcasts will be accessible on the Investor Relations page of Juno’s website at www.JunoTherapeutics.com. A replay of each presentation will be available at the same location for 30 days following the corresponding conference.

On November 6, 2017 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that it will deliver pre-clinical data on its Combination Pan-antigen Cytotoxic Therapy (ComPACT) platform on November 11, 2017, at the 32nd annual Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Heat Biologics, NOV 6, 2017, View Source [SID1234521582]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, Gp96-IG/costimulatory Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination, will be presented by Louis E. Gonzalez, Ph.D., director of research and principal scientist for Heat. He is available for discussion from 12:30 p.m. – 2 p.m. and 6:30 p.m. – 8 p.m. on Saturday, Nov. 11, 2017.

ComPACT is Heat’s next generation, T-cell Activation Platform (TCAP). It combines T-cell activation and co-stimulation in a single therapy by both delivering the gp96 heat shock protein and a T-cell co-stimulatory fusion protein (OX40L) in a single compound.

On November 6, 2017 STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, reported the appointment of Professor Paul Workman to its Board (Press release, STORM Therapeutics, NOV 6, 2017, View Source [SID1234561049]). This appointment continues STORM’s evolution of its management and advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO of STORM Therapeutics, Keith Blundy commented on the appointment: "I am pleased to welcome Paul asIndependent Director to STORM’s board. Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed. We look forward to Paul’s input on development and positioning of STORM’s emerging RNA epigenetics platform and programmes."

Professor Paul Workman, Chief Executive and President of The Institute of Cancer Research, London, said: "I am delighted to be joining the board of STORM and working with the company in this exploding area of biology. RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. I look forward to working with the board to help guide STORM’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech."

On November 6, 2017 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that the company is moving its conference call that was scheduled for 5:00 p.m. ET today to 8:00 a.m. ET tomorrow morning (Press release, Keryx Biopharmaceuticals, NOV 6, 2017, View Source;p=RssLanding&cat=news&id=2314738 [SID1234521608]). The company’s Prescription Drug User Fee Act (PDUFA) target action date for its supplemental new drug application for Auryxia is today, November 6, 2017. As of the time of this press release, the company has not received a response from the FDA. As such, Keryx has decided to move its third quarter financial results call to tomorrow.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619. The call will be webcast live and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.

Heron Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Heron Therapeutics, 2017, NOV 6, 2017, View Source [SID1234521578]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!